Subject(s)
Humans , Female , Pregnancy , Adolescent , Ascaridida Infections/diagnosis , Head and Neck Neoplasms/diagnosis , Thiabendazole/therapeutic use , Biopsy , Levamisole/therapeutic use , Ascaridida Infections/surgery , Ascaridida Infections/pathology , Ascaridida Infections/drug therapy , Rare Diseases/diagnosis , Rare Diseases/parasitology , Diagnosis, Differential , Drug Therapy, Combination , Anthelmintics/therapeutic use , Neck/pathologyABSTRACT
Human lagochilascariasis (HL) is a parasite produced by Lagochilascaris minor Leiper 1909 that also can be found in cats and dogs. HL is considered an emerging zoonosis in the Americas, spreading from Mexico to Argentina, and the Caribbean Islands. The present paper describes three HL cases from the Peninsula of Yucatan, Mexico, recorded in the last decade. It describes the characteristics of the lesions and discusses the route of transmission in humans and particularly in the observed patients.
La Lagochilascariasis humana (HL) es producida por Lagochilascaris minor Leiper, 1909; el cual es un parásito que puede ser encontrado también en gatos y perros. HL es considerada una zoonosis emergente en América distribuida desde México hasta Argentina y las islas del Caribe. El presente artículo describe tres casos de HL en la Península de Yucatán, México registrados en la última década. Se describen las características de las lesiones y se discute la ruta de transmisión en humanos y particularmente en los pacientes observados.
Subject(s)
Adolescent , Aged , Animals , Female , Humans , Male , Middle Aged , Ascaridida Infections/diagnosis , Ascaridida/isolation & purification , Albendazole/therapeutic use , Antinematodal Agents/therapeutic use , Ascaridida Infections/drug therapy , Mexico , Pyrantel Pamoate/therapeutic useABSTRACT
The comparative efficacy of 2 anthelmintics (ivermectin and levamisole) against Baylisascaris transfuga migrating and encapsulated larvae was studied in mice. A total of 60 BALB/c mice inoculated each with about 1,000 embryonated B. transfuga eggs were equally divided into 6 groups (A-F) randomly. Mice of groups A and B were treated with ivermectin and levamisole, respectively, on day 3 post-infection (PI). Mice of groups A-C were killed on day 13 PI. Similarly, groups D and E were treated with ivermectin and levamisole, respectively, on day 14 PI, and all mice of groups D-F were treated on day 24 PI. The groups C and F were controls. Microexamination was conducted to count the larvae recovering from each mouse. The percentages of reduction in the number of migrating larvae recovered from group A (ivermectin) and B (levamisole) were 88.3% and 81.1%, respectively. In addition, the reduction in encapsulated larvae counts achieved by ivermectin (group D) and levamisole (group E) was 75.0% and 49.2%, respectively. The results suggested that, to a certain extent, both anthelmintics appeared to be more effective against migrating larvae than encapsulated larvae. However, in the incipient stage of infection, ivermectin may be more competent than levamisole as a larvicidal drug for B. transfuga.